---
schema_version: "secwatch.filing_event.v1"
accession: "0001372514-24-000027"
form_type: "8-K"
ticker: "KPRX"
cik: "0001372514"
company_name: "KIORA PHARMACEUTICALS INC"
filed_at: "2024-03-25T23:59:59+00:00"
generated_at: "2026-06-04T08:22:45.346878+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Kiora reports 2023 net loss $12.5M; cash >$30M post partnership and placement

## Summary
- Net loss $12.5M in 2023 vs $13.6M in 2022; R&D expense $4.0M, G&A $4.7M.
- Cash and equivalents $2.5M at year-end 2023; $16M upfront from TOI partnership and $13.8M private placement net proceeds in Feb 2024 raised cash >$30M.
- Company expects existing cash to fund operations through 2026.
- KIO-301 Phase 2 trial in retinitis pigmentosa expected to start Q4 2024; KIO-104 Phase 2 planning underway.
- Partnership with Théa Open Innovation grants exclusive rights to KIO-301 outside Asia; potential milestones up to $285M plus tiered royalties.

## SEC filing metadata
- accession: 0001372514-24-000027
- form_type: 8-K
- ticker: KPRX
- cik: 0001372514
- company_name: KIORA PHARMACEUTICALS INC
- filed_at: 2024-03-25T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372514/000137251424000027/0001372514-24-000027-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372514/000137251424000027/kprx-20240325.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001372514-24-000027
- JSON: https://secwatch.observer/filing/0001372514-24-000027.json
- Plain text: https://secwatch.observer/filing/0001372514-24-000027.txt

## Key facts
- Earnings Releases
  KIORA PHARMACEUTICALS INC reported financial results for the year ended December 31, 2023.
  - Period: the year ended December 31, 2023
  - Result: reported results
  source text: Kiora Pharmaceuticals, Inc. (the "Company") issued a press release announcing financial results for the year ended December 31, 2023 and an update on clinical development progress.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1372514/000137251424000027/0001372514-24-000027-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.